Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy

DALLAS: Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai - the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform’s capabilities and commercial architecture, the rare cancer market opportunity, competitive positioning, and the Company’s near-term revenue strategy and growth roadmap. Registration is available at: Zoom link https://us06web.zoom.us/webinar/register/1017749924357/WN_o7JaBBCxRDSfEzN6eUCwQA.

The withZeta.ai Briefing

The investor and analyst briefing will be hosted by Panna Sharma, President and Chief Executive Officer and Kishor Bhatia, Ph.D., FRCP, Chief Scientific Officer of Lantern Pharma, and will cover the following:

1. The rare cancer imperative - why millions of patients across hundreds of distinct cancer types remain systemically underserved and why AI co-scientists are part of the solution
2. Live demonstration of withZeta.ai - the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design
3. Platform capabilities and what makes withZeta.ai fundamentally different and an economic imperative in drug discovery and development.
4. Commercial subscription model, revenue strategy, and market opportunity
5. Competitive position in the AI drug discovery landscape
6. Strategic roadmap and upcoming milestones for withZeta.ai

“withZeta.ai is built on a foundation that took years of our team’s work to ideate and assemble - 12 FDA designations across orphan, pediatric rare disease, and fast track classifications for Lantern, and several more earned by our collaborators. We have three drugs in precision oncology clinical trials with over 100 patients successfully dosed and studied. That heritage of clinical and regulatory recognition and rare cancer expertise is baked into every layer of the platform. Knowledge work in oncology is migrating to AI co-scientists and we intend to help lead that migration and empower scientists towards an era of hyper productivity and breakthroughs for patients. On April 9th we plan to show our investors and shareholders exactly what that looks like in practice - the multi-agentic architecture, the science, and the commercial model that makes withZeta.ai a durable and highly unique revenue engine for Lantern. The future of drug discovery will be co-developed with advances in AGI and multi-agentic systems.”
-Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.

The Co-Scientist AI Platform

withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists - autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere.

withZeta.ai’s multi-agentic architecture enables autonomous recursive research workflows that simultaneously query proprietary rare cancer knowledge bases, published scientific literature, registered clinical trials, and molecular databases - reasoning across all of them to deliver insights that would take human research teams weeks or months to assemble. The platform’s living knowledge graph evolves dynamically with each research session, transforming scientific conversations into navigable semantic maps of diseases, drugs, genes, pathways, and clinical trials.

The Commercial Opportunity

The briefing of the multi-agentic AI platform will include a full presentation of withZeta.ai’s commercial subscription model - spanning from individual researchers and academic institutions to innovative biopharma companies and global pharma partnerships - along with the Company’s near-term revenue strategy and growth roadmap. Specific pricing and market projections will be presented live during the event.

“The global AI drug discovery and development market is projected to exceed $15 billion by 2030 - with oncology leading all therapeutic areas - and rare cancers represent the most underserved and highest-urgency opportunity within it. withZeta.ai is positioned to capture a meaningful share of that market through a scalable subscription architecture spanning individual researchers, academic institutions, innovative biopharma companies, and global pharma enterprises. The platform’s combination of proprietary rare cancer ontologies, multi-agentic architecture, and a decade of clinical and regulatory expertise creates a defensible position that general-purpose AI platforms simply cannot replicate. April 9th is an opportunity for our investors to see a glimpse into this meaningful and already deployed commercial picture. Rare cancer patients should not have to wait decades for insights, opportunities, therapies, and thoughtful trials. Our platform - an AI for good - withZeta.ai has a real opportunity to lead the change in that dynamic.”
-Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.

Experience & Briefing Details

Date: Thursday, April 9, 2026

Time: 8:30 AM Eastern / 5:30 AM Pacific

Format: Live webcast with Q&A

Registration: https://us06web.zoom.us/webinar/register/1017749924357/WN_o7JaBBCxRDSfEzN6eUCwQA

Replay: An archived replay will be available on Lantern Pharma’s investor relations website at ir.lanternpharma.com as well as at withzeta.ai following the event.

Investors and analysts with questions in advance of the briefing may contact Lantern Pharma’s investor relations team at ir@lanternpharma.com or +1-972-277-1136.

ABOUT LANTERN PHARMA INC.

Lantern Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development and generate oncology medicines at dramatically reduced costs and accelerated timelines. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program.

Our lead development programs include a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.

ABOUT withZeta.ai

withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists - autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere. Built by Lantern Pharma (Nasdaq: LTRN). Learn more at withzeta.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform and withZeta.ai platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; the planned commercialization of our AI platforms including withZeta.ai and the expected market opportunity for AI co-scientist platforms; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, (vii) the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the expected market adoption, and (viii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.

You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Lantern Pharma Inc. | Nasdaq: LTRN | withZeta.ai

Fonte: Business Wire